Click Therapeutics logo

Click Therapeutics

Developer of prescription digital therapeutics, including Motivista for negative symptoms of schizophrenia.

ShareLink copied

The record

Vertical
Mental & Behavioral Health
Sub-segment
Prescription digital therapeutics
Product type
Software as a medical device
Stage
Series D
Headquarters
New York, New York
Region
North America
Founded
2012

What they do

Motivista, also known as CT-155, is a prescription digital therapeutic for negative symptoms of schizophrenia in adults with clinically stable positive symptoms. It is used alongside clinician-managed outpatient care, including antipsychotics. FDA granted 510(k) clearance in October 2026 following the Phase III CONVOKE study. Click describes it as the first FDA-authorised treatment for that indication. Boehringer Ingelheim's April 2026 investment also transferred full product responsibility and commercial and marketing authorisation rights to Click.

Leadership & founders

Leadership as of 14 November 2026.

Investors

  • Boehringer Ingelheim

History and progression

How Click Therapeutics got here, step by step.

  1. 2024

    Breakthrough Device Designation

    FDA granted Breakthrough Device Designation to CT-155.

  2. 9 April 2026

    $50 million Series D from Boehringer Ingelheim

    Boehringer Ingelheim made a $50M Series D strategic investment plus dedicated commercial funding and transferred full product responsibility for CT-155, including commercial and marketing authorisation rights, to Click.

  3. 5 October 2026

    FDA clears Motivista (CT-155)

    510(k) clearance for Motivista, a prescription digital therapeutic for negative symptoms of schizophrenia; the company says it is the first FDA-authorised treatment for that indication. Supported by the Phase III CONVOKE study.

Key products

Motivista (CT-155)
Prescription digital therapeutic for negative symptoms of schizophrenia in adults with clinically stable positive symptoms, as an adjunct to clinician-managed outpatient care including antipsychotics

Recent news

  1. 5 October 2026

    FDA clears Motivista (CT-155)
  2. 9 April 2026

    Click Therapeutics and Boehringer Ingelheim announce Series D investment

Topic: Prescription digital therapeutics

Topic: Prescription digital therapeutics

In our newsletter

Related companies

Your daily HealthTech Signal

No hype. Just signal.

Get the latest HealthTech news, understand why it matters, and see where the industry is headed.

5-minute read Delivered daily Unsubscribe anytime

Read by teams at companies like:

Mayo Clinic logoMayo ClinicCleveland Clinic logoCleveland ClinicJohns Hopkins logoJohns HopkinsKaiser Permanente logoKaiser PermanenteEpic logoEpicPhilips logoPhilipsMedtronic logoMedtronicGE HealthCare logoGE HealthCare

Is this your company? Get a Verified profile